CSG Awarded Patent for Zero-Code Ecosystem Design
B2C-style experiences with instant gratification and offer personalization are the new standards for all industries and communication service providers (CSPs) are not immune to this pressure. To lead CSPs into this new era of customer experience, CSG® (NASDAQ: CSGS) announced that it has been awarded a patent in the US and Australia for CSG Encompass. The platform enables telcos to expand their portfolios with products and services from partners and tap into the promise of a lucrative B2B2X market. The patent anchors CSG's position as an industry leader in B2B2X and protects its unique design for powering a frictionless user experience.
“CSPs need a catalogue-driven solution that allows flexible, scalable and repeatable collaboration across partners to capitalize on the evolving opportunities in B2B2X,” said Greg Tilton, VP Catalogue, Quote & Order, CSG. “CSG Encompass does exactly that. It allows operators to launch new services faster and seamlessly bolster their business with more personalized customer experiences for both the enterprise and consumers. To be granted this patent is a significant milestone for CSG, and we are proud to lead the industry with a solution proven to make it easier for CSPs to move beyond connectivity."
CSG Encompass allows CSPs to easily create, bundle, and launch new products and services. With CSG's patented solution, offers can be built from CSP and partner components and then quoted, ordered, and managed with zero code required. Built on TM Forum ODA and Open API standards, this technology means partnerships between CSPs and their partners can be created with zero IT integration cost. Doing so makes it easier, faster and cheaper for CSPs to offer innovative new products and services.
“Enterprises and their partners alike want to interact and transact digitally without having to make significant investments into the creation of components from multiple suppliers themselves,” said John Abraham, principal analyst, Appledore Research. “B2B2X ecosystems, which bring together digital services from several partners, are the foundation for delivering these seamless experiences. To be successful, they require an open, integrated solution that can manage the complex commerce cycles needed for CSPs to engage with a more diverse range of partners. This patent reinforces CSG’s emphasis on helping telco operators resolve the complexities of B2B2X marketplaces and capitalize on new monetization opportunities.”
Recognized as a TM Forum Catalyst finalist with the first phase of its Channel & Markets project, CSG has proven Encompass as the most effective end-to-end platform to solve the B2B2X zero-touch challenge. The second phase now tests some proposed enhancements to API standards and will be showcased during DTW Asia 2023. From the outset, CSG has been a significant contributor to the MEF SONATA SDK and TM Forum Open APIs. This patent is a testament to CSG's commitment to advancing the industry and enabling CSPs to use these standards effectively and successfully to thrive in the digital economy and beyond.
About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our more than 5k-strong experienced global CSG services team.
Want to learn more about how to be a change-maker and industry shaper like our 1,000-plus clients? Visit csgi.com to learn more.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005005/en/
Contact information
Kristine Østergaard
Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com
John Rea
Investor Relations
+1 (210) 687-4409
john.rea@csgi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
FieldBee Vision wins Gold for Digital Technology Innovation at LAMMA 20269.1.2026 06:25:00 EET | Press release
FieldBee, the European leader in high-quality, easy-to-use and affordable precision agriculture technologies, proudly announces that FieldBee Vision has earned global recognition, becoming the Gold Winner in the Digital Technology Innovation of the Year category at the LAMMA Innovation Awards 2026. Lamma Show is the UK’s premier agricultural machinery, technology and equipment innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107606411/en/ FieldBee wins the LAMMA Innovation Award 2026 for Digital Technology Innovation of the Year for the FieldBee Vision (VisionSteer & VisionPro) system FieldBee Vision is part of the newly launched myFieldBee ecosystem, built to unify FieldBee’s precision farming tools and designed to connect navigation, autosteering, ISOBUS into one unified platform that supports planning, execution, monitoring and reporting. FieldBee Vision, the first modular retrofit agricultural vision system,
Survey Finds Over 70% of Chinese Doctors Recommend “AI Doctor Services” Like Ant Group’s AQ for Everyday Health Needs9.1.2026 05:31:00 EET | Press release
A recent survey by Life Times, a well-known Chinese public health media outlet, shows that AI doctor services are broadly supported by doctors in China. Among 500 physicians from the country’s top-tier (tertiary) hospitals, more than 70% said they would recommend AI doctor services to patients for everyday health questions and routine health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108456917/en/ Ant Group’s AI-native health app AQ is designed to address common, everyday health concerns and support healthy habit formation. Ant Group’s AQ was the most frequently recommended platform in the survey. The latest figures show that, as of January 2026, the app had accumulated 30 million monthly active users and answers over 10 million health-related questions daily, making it China’s leading AI-native health app. AQ—known in Chinese as Ant A-Fu—is an AI-native health app launched by Ant Group in June 2025. Desig
OPPO Joins VVC Advance Patent Pool as a Licensee and Extends HEVC Advance License9.1.2026 04:00:00 EET | Press release
Access Advance LLC and Guangdong OPPO Mobile Telecommunications Corp., Ltd. (OPPO) today announced that OPPO has joined the VVC Advance Patent Pool as a Licensee and renewed its HEVC Advance License. OPPO, one of the world's largest smartphone manufacturers with operations in more than 70 countries, has been a valued participant in Access Advance's HEVC patent pool since 2020, and more recently joined the Advance Video Distribution Patent (VDP) Pool as a Licensor. These latest agreements mark a new milestone in a broad and deepening relationship between the two companies, with OPPO now participating across all three of Access Advance's video codec licensing programs. The VVC Advance Patent Pool licenses patents essential to the VVC/H.266 standard, which delivers remarkable improvement of video compression performance over HEVC, enabling higher-quality video experiences including 4K, 8K, and HDR content with faster downloads and lower latency. The pool currently includes over 4,500 worl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom